NIS-observe Treatment Efficacy in Maintaining Symptoms Control in Moderate/Severe Asthma With Symbicort SMART
Completed
- Conditions
- Moderate/Severe Asthma
- Registration Number
- NCT00785733
- Lead Sponsor
- AstraZeneca
- Brief Summary
The primary objective of this non-interventional study is to evaluate efficacy of Symbicort® SMART treatment in adult patients with moderate to severe asthma using ACQ scores during 6 months period
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1182
Inclusion Criteria
- patients eligible for entry into study are the patients diagnosed with moderate to severe asthma, that the doctors have already decided to treat with Symbicort SMART within the last month, before inclusion in this program
- All eligible patients will be included in the protocol provided they will receive detailed information in advance and will sign consent to grant access to their own data collected during this programme.
Exclusion Criteria
- All the patients who have a known hypersensitivity to Symbicort or any of its excipients will not be included in this study.
- As per valid Romanian SmPC, concomitant medication, that could result in drug interactions and could jeopardise patient safety will be carefully considered before having the patient enrolled.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Asthma Control Questionnaire ACQ 5 visits (V1-week 0, V2-week 4, V3-week 8, V4-week 16, V5-week 24)
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Symbicort® SMART's efficacy in moderate/severe asthma?
How does Symbicort® SMART compare to standard ICS/LABA therapies in asthma control?
Which biomarkers correlate with improved ACQ scores in Symbicort® SMART treatment?
What adverse events are associated with budesonide/formoterol combination therapy?
Are there alternative long-acting beta-agonist approaches for asthma maintenance therapy?
Trial Locations
- Locations (1)
Research Site
🇷🇴Zalau, Romania
Research Site🇷🇴Zalau, Romania